Alveolar Capillary Dysplasia (ACD/MPV)

Alveolar capillary dysplasia (ACD) is a very rare birth condition that affects a baby’s lungs. In ACD, the tiny blood vessels (capillaries) that should sit right next to the air sacs (alveoli) are too few and sit in the wrong place. Small veins also run in the wrong path (“misalignment”). Because of this, oxygen cannot move well from air to blood. The baby develops severe low oxygen and very high blood pressure in the lungs (pulmonary hypertension) soon after birth. Most babies become sick within the first day of life. A small number have a milder or “atypical” form and show symptoms later in infancy. The condition is usually fatal without lung transplantation. PMC

Alveolar capillary dysplasia with misalignment of the pulmonary veins—often shortened to ACD/MPV or simply ACD—is a rare, serious lung problem that starts before birth. In ACD, the tiny air sacs in the lungs (alveoli) and the tiny blood vessels that should sit right next to them (capillaries) do not form in the usual way. Because of this poor design, oxygen cannot easily move from the air in the lungs into the blood. At the same time, some pulmonary veins run in the wrong place, side-by-side with the small arteries and airways, instead of in their normal path. These changes cause severe low oxygen and high pressure in the lung arteries (pulmonary hypertension) very soon after birth. Most babies show breathing trouble within hours, and the condition is often life-threatening despite strong treatment. PMC+2PMC+2

Scientists have learned that many cases come from changes (mutations or deletions) in a gene called FOXF1 or in a control region (enhancer) near this gene. FOXF1 helps guide how the lungs and their blood vessels form in the embryo. When FOXF1 does not work correctly, the lung’s tiny air–blood interface stays underdeveloped, and the blood vessels are misplaced or too few. MedlinePlus+1

ACD can also come with problems in other organs that develop around the same time in the embryo, especially the intestines and other parts of the digestive tract, the heart, and the kidneys/urinary system. These extra findings make doctors think about ACD when a newborn has severe breathing trouble plus certain birth defects, particularly intestinal malrotation. Wiley Online Library+1

Other names

• Alveolar capillary dysplasia with misalignment of the pulmonary veins (full name)

• ACD/MPV or ACDMPV (common abbreviations)

• Congenital alveolar capillary dysplasia (emphasizes that it is present at birth)

All three terms point to the same disorder. Genetic Rare Disease Center+1

Types

ACD/MPV is one disease, but doctors sometimes group it into practical “types” based on how and when it appears, what the lung tissue looks like, and what gene changes are found:

1. Classic, early-onset ACD/MPV. The most common pattern. A term or near-term baby develops severe low oxygen and pulmonary hypertension in the first hours of life and does not respond to usual therapies (oxygen, ventilation, inhaled nitric oxide). PMC

2. Atypical or “late-presenting” ACD/MPV. A smaller group have milder or patchy lung involvement. They may improve for days or weeks, then suddenly develop hard-to-treat hypoxemia and pulmonary hypertension. Lung biopsy or genetic testing reveals ACD features. PMC

3. Patchy ACD/MPV. Under the microscope, some areas of lung look closer to normal while other areas show the typical ACD pattern. This patchiness can explain delayed or fluctuating symptoms. PMC

4. Genetically defined ACD/MPV. Changes directly in the FOXF1 gene (missense, nonsense, frameshift, splice-site) or copy-number changes that delete FOXF1 or its upstream enhancer at chromosome 16q24.1. These genetic subtypes are important for family counseling. BioMed Central+2ScienceDirect+2

5. ACD/MPV with major extra-pulmonary anomalies. Many affected newborns also have intestinal malrotation or other gastrointestinal, heart, or genitourinary defects; this cluster can alert the team to test for ACD. Wiley Online Library

Causes

ACD/MPV is a developmental disease. In most cases, the core cause is FOXF1 haploinsufficiency—meaning one working copy of FOXF1 is not enough during lung development. Below are causes and well-supported contributors grouped for clarity. Where the science is emerging, that is noted.

1. FOXF1 missense mutations. A single “letter” change that alters the FOXF1 protein’s amino acid sequence can weaken its function and lead to ACD/MPV. BioMed Central

2. FOXF1 nonsense or frameshift mutations. These create truncated proteins or disrupt FOXF1 completely, producing classic ACD/MPV. PMC

3. FOXF1 splice-site mutations. Changes that disturb how FOXF1 RNA is spliced can inactivate the gene. PMC

4. FOXF1 whole-gene deletions. Removing the gene itself causes FOXF1 haploinsufficiency. Europe PMC

5. Deletions of the distant FOXF1 lung enhancer (16q24.1). Losing this regulatory DNA reduces FOXF1 expression enough to cause ACD/MPV; many such deletions are on the maternal chromosome. PMC

6. Copy-number variants in 16q24.1 that include FOXF1 or its enhancer. Larger genomic rearrangements spanning the FOX gene cluster (FOXF1/FOXC2/FOXL1) can produce ACD/MPV and associated malformations. ScienceDirect

7. De novo (new) mutations. Most FOXF1 changes arise for the first time in the child (not inherited), explaining why there is often no family history. PubMed

8. Familial cases with autosomal-dominant transmission. Rare families show inheritance across generations, consistent with a dominant effect with variable expression. Nature

9. Altered enhancer activity and epigenetic effects. Research suggests that methylation and parent-of-origin effects at the enhancer modulate FOXF1 levels; enhancer loss on the maternal allele is repeatedly observed. (Active area of study.) openaccess.sgul.ac.uk+1

10. Regulatory region point mutations. Not only big deletions but also small changes in the enhancer can reduce FOXF1 expression. (Less common but documented.) Europe PMC

11. Chromosomal rearrangements disrupting long-range FOXF1 regulation. Translocations or inversions near 16q24.1 may uncouple FOXF1 from its enhancer. ScienceDirect

12. Functional impairment of FOXF1 protein. Laboratory work shows certain missense variants blunt FOXF1’s DNA-binding/transcriptional activity, pushing development off course. BioMed Central

13. Insufficient pulmonary mesenchyme signaling. Because FOXF1 acts in lung mesenchyme, loss of function disturbs vessel formation cues (e.g., VEGF pathways), yielding sparse, distant capillaries. PMC

14. Developmental misrouting of pulmonary veins. The venous channels take an abnormal path alongside arteries/airways, a hallmark microscopic feature tied to the same developmental error. PMC

15. Associated developmental field defects. FOXF1 is also active in the gut; its disruption can co-produce intestinal malrotation and other anomalies alongside the lung defects. MedlinePlus+1

16. Maternal-allele enhancer deletions (parent-of-origin bias). Many pathogenic enhancer deletions arise on the maternal chromosome, supporting a parent-of-origin effect in expression control. PMC

17. Duplications or dosage imbalance of nearby FOX genes. Complex CNVs in the FOX cluster can perturb gene networks during organogenesis and have been linked to ACD/MPV. Europe PMC

18. Genetic mosaicism in a parent. A parent may have the variant in only some cells and be healthy but still pass it to a child; this explains rare recurrences in families without obvious disease. (Documented mechanism in similar congenital conditions; suspected in ACD/MPV.) Nature

19. Unidentified genetic factors. A minority of clinically and pathologically proven cases have no detectable FOXF1/enhancer change with current testing, suggesting other genes or cryptic variants. PMC

20. Epigenetic or enhancer-structure changes still under investigation. New work continues to refine how the 16q24.1 enhancer units and imprinting-like effects shape FOXF1 output and disease risk. (Research frontier, not a clinical test yet.) BioMed Central+1

Common symptoms and signs

Most babies with ACD/MPV look well at birth but develop severe breathing trouble within hours to a day or two. The items below are typical features.

1. Fast breathing and working hard to breathe (chest retractions, flaring nostrils, grunting). This reflects poor oxygen transfer. PMC

2. Blue or gray skin color (cyanosis). Seen on lips and nails due to low oxygen in the blood. PMC

3. Very low oxygen levels that don’t improve with high-flow oxygen or a ventilator. This “refractory hypoxemia” is a red flag. PMC

4. Severe pulmonary hypertension (high pressure in lung arteries) causing right-to-left shunting of blood. PMC

5. Poor response to inhaled nitric oxide. Unlike many other newborn lung problems, ACD/MPV usually responds poorly to nitric oxide therapy. PMC

6. Low blood pressure and poor perfusion as the heart struggles against lung artery pressure. PMC

7. Right-sided heart strain (can show on echocardiogram/ECG). PMC

8. Acid build-up in the blood (acidosis) due to ongoing low oxygen. PMC

9. Feeding problems or abdominal swelling, sometimes tied to associated intestinal malrotation or other GI anomalies. Wiley Online Library

10. Need for high ventilator settings or ECMO (heart-lung bypass), often with little lasting improvement. PMC

11. Low oxygen difference between pre- and post-ductal sites may persist despite therapy because of shunting. PMC

12. Crackles or relatively quiet lungs on exam. The chest exam can be non-specific even when oxygen is very low. PMC

13. Chest x-ray that looks mild compared with the baby’s severe condition. Imaging may show only subtle changes early on. PMC

14. Co-existing birth defects (e.g., intestinal or cardiac) that raise suspicion for a syndromic developmental problem. Wiley Online Library

15. Late presentation in rare cases. Some infants seem stable for days or weeks before sudden decompensation, especially with patchy disease. PMC

Diagnostic tests

A) Physical examination

1. General newborn exam. Doctors look for fast breathing, chest retractions, nasal flaring, and cyanosis. In ACD, distress is severe and appears early. The overall picture seems “too bad” for what routine x-rays show. PMC

2. Cardiovascular exam. A loud second heart sound (accentuated P2) or signs of right-sided strain suggest pulmonary hypertension, common in ACD. PMC

3. Pre- vs. post-ductal oxygen saturation check. Comparing a hand (pre-ductal) and a foot (post-ductal) pulse oximeter can show right-to-left shunting; in ACD, numbers often stay low despite oxygen. PMC

4. Exam for associated anomalies. A gentle abdominal exam for malrotation/obstruction signs, genital or kidney differences, or murmurs helps point toward a developmental syndrome like ACD. Wiley Online Library

B) Manual/bedside functional tests

5. Response to 100% oxygen (“hyperoxia test”). In many newborn lung problems, oxygen levels rise on pure oxygen; in ACD, the rise is small or absent because the air–blood interface is fundamentally faulty. PMC

6. Trial of inhaled nitric oxide. Lack of meaningful improvement in oxygenation despite nitric oxide suggests fixed or diffuse vascular underdevelopment as in ACD. PMC

7. Gentle lung ultrasound at bedside. Bedside ultrasound may show nonspecific interstitial patterns and helps rule out pneumothorax or pleural fluid; a mismatch between severe hypoxemia and limited sonographic findings supports considering ACD. SpringerOpen

8. High-frequency ventilation trial. Used in practice, not as a formal “test,” but failure to improve oxygenation despite escalation often triggers the ACD work-up. PMC

C) Laboratory and pathological tests

9. Arterial blood gas (ABG). Shows severe hypoxemia and often acidosis; values stay poor despite high oxygen support. This helps quantify disease severity. PMC

10. Cardiac markers (BNP/NT-proBNP). May be elevated with right heart strain from pulmonary hypertension; supports the hemodynamic picture. PMC

11. Genetic testing—FOXF1 sequencing. Finds point mutations or small insertions/deletions in FOXF1; a positive result strongly supports the diagnosis and can spare high-risk biopsy. MedlinePlus

12. Genetic testing—chromosomal microarray or targeted CNV analysis. Detects deletions of FOXF1 or its upstream enhancer at 16q24.1. These changes are a major known cause. ScienceDirect+1

13. Targeted testing for parental origin (when a deletion is found). Many enhancer deletions are on the maternal allele; parent-of-origin studies help interpret results and counsel families. PMC

14. Surgical lung biopsy (when clinically safe and genetics are negative or unclear). The gold-standard tissue pattern shows too few capillaries set back from the alveolar lining, thickened septa, small artery muscle thickening, lymphatic dilation, and pulmonary veins running abnormally with arteries/airways. In practice, biopsy is often avoided if the baby is unstable; some diagnoses are confirmed at autopsy. PMC

15. Histopathology review by an experienced pediatric lung pathologist. Expert eyes are important because ACD can be patchy and subtle; misalignment of veins and paucity of capillaries clinch the diagnosis. PMC

D) Electrodiagnostic and monitoring tests

16. Continuous pulse oximetry. Tracks how low the oxygen saturation remains despite therapy and documents pre/post-ductal differences from shunting. PMC

17. Electrocardiogram (ECG). May show right-ventricular strain or hypertrophy, supporting the presence of significant pulmonary hypertension. PMC

18. Near-infrared spectroscopy (NIRS), when available. Monitors brain or tissue oxygenation; persistent low readings alongside low arterial saturations underscore the severity of gas-exchange failure. (Supportive, not diagnostic by itself.) PMC

E) Imaging tests

19. Chest radiograph (x-ray). Often surprisingly mild or nonspecific—maybe hazy lungs or prominent pulmonary arteries—despite very sick oxygen levels. The mismatch raises suspicion. PMC

20. Echocardiogram (heart ultrasound). Shows pulmonary hypertension and right-sided strain, rules out structural heart disease, and may show right-to-left shunting across the ductus arteriosus or foramen ovale. A normal heart with severe pulmonary hypertension in a newborn should prompt thinking about ACD. PMC

21. High-resolution chest CT (when baby is stable enough). May show diffuse interstitial changes but is not specific; it mainly excludes other causes. CT is rarely decisive for ACD. PMC

22. Targeted fetal/prenatal imaging review. Looking back at prenatal scans can reveal associated anomalies (e.g., intestinal malrotation, abdominal wall defects) that fit the ACD pattern. Wiley Online Library

23. Advanced morphomolecular work-ups in research settings. Some centers apply combined morphology–molecular approaches to better define borderline cases and understand mechanisms, but these are not routine clinical tests. American Journal of Pathology

Non-pharmacological treatments (therapies & other supports)

These are hospital/NICU therapies. They are tailored by specialists for each baby.

1. Gentle conventional ventilation
   Purpose: support breathing and limit lung injury.
   Mechanism: lower pressures and careful oxygen targets to avoid barotrauma and oxidative injury while maximizing gas exchange. PMC

2. High-frequency ventilation (HFOV/HFJV)
   Purpose: improve oxygenation with tiny rapid breaths when conventional ventilation fails.
   Mechanism: stabilizes alveoli, improves mean airway pressure, can enhance oxygen diffusion despite poor capillary network. PMC

3. Careful oxygen titration
   Purpose: treat hypoxemia but avoid oxygen toxicity.
   Mechanism: raises alveolar oxygen to drive diffusion; frequent blood gases guide targets. PMC

4. Prone positioning and meticulous nursing care
   Purpose: improve ventilation-perfusion matching and comfort.
   Mechanism: position change shifts lung mechanics to better-aerated areas. PMC

5. Thermal neutrality and minimal handling
   Purpose: reduce oxygen demand and stress-related pulmonary vasoconstriction.
   Mechanism: prevents cold stress and catecholamine surges that raise pulmonary pressure. PMC

6. Cardiorespiratory monitoring (ECG, pulse oximetry, NIRS)
   Purpose: detect desaturation and hemodynamic swings early.
   Mechanism: continuous feedback lets clinicians titrate therapies moment-to-moment. PMC

7. Echocardiography-guided care
   Purpose: confirm pulmonary hypertension, rule out heart defects, guide therapy.
   Mechanism: ultrasound measures right-sided pressures and shunts, informing treatment choices. PMC

8. Hemodynamic optimization (fluids/diuresis)
   Purpose: keep the right heart working and avoid lung edema.
   Mechanism: careful fluids maintain preload; diuretics offload the circulation when needed. PMC

9. Nutritional support (TPN, then tube feeds)
   Purpose: provide calories for healing when oral feeds are unsafe.
   Mechanism: parenteral nutrition early; later human milk via tube if stable. (Feeding plan is highly individualized in ACD.) PMC

10. Infection prevention bundles
    Purpose: avoid sepsis that worsens pulmonary hypertension.
    Mechanism: sterile lines, antibiotic stewardship, NICU hygiene practices. PMC

11. Pain and stress control
    Purpose: lower oxygen consumption and pulmonary vasoconstriction.
    Mechanism: judicious sedation/comfort measures reduce stress responses. PMC

12. Weaning strategies & extubation readiness protocols
    Purpose: reduce ventilator days and complications when feasible (rare in classic ACD).
    Mechanism: gradual support reduction based on objective readiness checks. PMC

13. Family-centered care & counseling
    Purpose: informed decision-making, including palliative options.
    Mechanism: honest discussions about expected course and options, including transplant evaluation. PMC

14. Early involvement of transplant team (when atypical/milder disease)
    Purpose: assess candidacy and timing.
    Mechanism: multidisciplinary evaluation and listing if appropriate. PMC

15. ECMO (Extracorporeal Membrane Oxygenation) as bridge
    Purpose: temporary heart-lung support when conventional care fails, occasionally as bridge to diagnosis or transplant.
    Mechanism: pumps blood through an artificial lung outside the body allowing lung rest. Universitätsklinikum Regensburg+1

16. Avoidance of excessive ventilator pressures
    Purpose: prevent pneumothorax (common with stiff, injured lungs).
    Mechanism: lung-protective settings. PMC

17. Judicious use of open lung biopsy
    Purpose: tissue diagnosis when it will change decisions (ideally before ECMO).
    Mechanism: surgical sample shows classic ACD features under microscope. PMC

18. Transport to tertiary NICU
    Purpose: access to advanced ventilation, ECMO, genetics, and transplant expertise.
    Mechanism: coordinated neonatal transport and regionalized care. ELSO

19. Genetic testing & counseling (FOXF1)
    Purpose: confirm cause, inform family planning, consider prenatal options in future pregnancies.
    Mechanism: blood test for FOXF1 variants or 16q24.1 deletions; counseling explains recurrence risk. MedlinePlus

20. Palliative care integration
    Purpose: comfort-focused care when recovery is not possible.
    Mechanism: symptom relief, family support, and goal-concordant decisions. PMC

---

Drug treatments

Important: These medicines do not cure ACD; they treat pulmonary hypertension or support the heart/lungs. All dosing in newborns is specialist-only and individualized. Ranges below reflect published neonatal practice; they are not instructions for parents/caregivers. PubMed

1. Inhaled Nitric Oxide (iNO) — pulmonary vasodilator (gas)
   Typical NICU dose: start 20 ppm, titrate by response; wean when stable.
   Time: continuous via ventilator.
   Purpose: lower pulmonary vascular resistance, improve oxygenation.
   Mechanism: increases cGMP in smooth muscle → vasodilation.
   Side effects: rebound PH if stopped abruptly, methemoglobinemia (rare). Brigham and Women’s Hospital+1

2. Sildenafil — PDE-5 inhibitor
   Typical NICU practice: oral 0.5–2 mg/kg every 6–8 h; or IV loading ~0.4 mg/kg over 3 h then ~1.6 mg/kg/day infusion in studies.
   Time: ongoing if helpful; taper as tolerated.
   Purpose: augment cGMP pathway; rescue or weaning aid from iNO.
   Side effects: systemic hypotension, reflux; monitor BP. PMC+2theijcp.org+2

3. Milrinone — PDE-3 inhibitor/inodilator
   Typical NICU practice: load 50 µg/kg over 60 min (select cases), then 0.3–0.99 µg/kg/min infusion; loading may be omitted in hypotension.
   Purpose: improve right/left ventricular function; reduce afterload.
   Side effects: hypotension, arrhythmia; adjust with renal impairment. PMC+2AAP Publications+2

4. Prostaglandin E1 (alprostadil) — ductal dilator
   Dose (concept): continuous low-dose infusion to keep ductus arteriosus open when right heart off-loading is needed.
   Purpose: maintain right-to-left shunt to reduce RV strain (select cases).
   Side effects: apnea, hypotension; requires ventilation and ICU monitoring. PubMed

5. Epoprostenol/Iloprost/Treprostinil — prostacyclin analogs
   Use: inhaled or IV as adjuncts when iNO insufficient.
   Purpose: potent pulmonary vasodilation, anti-platelet effects.
   Risks: systemic hypotension; line complications (IV). Evidence in neonates is limited. PubMed

6. Bosentan — endothelin-receptor antagonist
   NICU evidence: small trials/series in PPHN suggest benefit as add-on; monitor liver enzymes.
   Purpose: block endothelin-mediated vasoconstriction.
   Side effects: hepatotoxicity, edema. (Evidence in PPHN evolving; not ACD-specific.) Cambridge University Press & Assessment+2PubMed+2

7. Dobutamine — inotrope
   Purpose: support cardiac output if ventricular function is low.
   Mechanism: β1-agonist increases contractility.
   Risks: tachycardia, arrhythmia; titrate by echo and perfusion. PubMed

8. Dopamine — vasopressor/inotrope
   Purpose: raise systemic BP to reduce right-to-left shunting.
   Risks: tachyarrhythmias, peripheral vasoconstriction. PubMed

9. Norepinephrine — vasopressor
   Purpose: stabilize systemic pressure when profound hypotension occurs.
   Risk: peripheral ischemia; continuous monitoring required. PubMed

10. Epinephrine — inotrope/vasopressor
    Purpose: support in refractory shock; improves inotropy and afterload.
    Risks: tachycardia, hyperglycemia, arrhythmias. PubMed

11. Furosemide — diuretic
    Purpose: treat pulmonary edema and optimize preload/afterload.
    Risks: electrolyte loss, ototoxicity with high doses/rapid IV push. PubMed

12. Empiric antibiotics (e.g., ampicillin + gentamicin per local protocol)
    Purpose: treat possible sepsis that can mimic/worsen PPHN.
    Risks: nephro/ototoxicity (aminoglycosides); stewardship essential. PubMed

13. Sedation/analgesia (fentanyl/morphine as per NICU protocol)
    Purpose: reduce agitation and oxygen demand; improve ventilation synchrony.
    Risks: respiratory depression, hypotension; careful titration needed. PubMed

14. Surfactant (select cases)
    Purpose: improve alveolar function if secondary surfactant deficiency suspected.
    Note: benefit in classic ACD is limited because the vascular problem dominates. PMC

15. Inhaled oxygen (a “drug” when prescribed)
    Purpose: treat hypoxemia.
    Risks: oxygen toxicity if excessive; careful targets required. PMC

16. Hydrocortisone (hemodynamic rescue, select cases)
    Purpose: treat catecholamine-refractory shock; reduce inflammation.
    Risks: hyperglycemia, infection risk; not disease-modifying for ACD. PubMed

17. Heparin (if on ECMO)
    Purpose: anticoagulation during extracorporeal support.
    Risks: bleeding, thrombosis if under- or over-treated; protocolized monitoring. PubMed

18. Inhaled prostacyclin
    Purpose: iNO alternative in centers with expertise.
    Mechanism: vasodilation via cAMP pathway.
    Risks: systemic spillover causing hypotension. PubMed

19. Metabolic support (e.g., sodium bicarbonate for severe acidosis)
    Purpose: correct acidosis that worsens pulmonary vasoconstriction.
    Note: use is targeted and controversial; guided by blood gases. PubMed

20. Combination pulmonary vasodilator therapy
    Purpose: in atypical ACD, combined iNO + sildenafil ± milrinone/bosentan sometimes improves hemodynamics.
    Evidence: case series; transient or partial responses are more common in classic ACD. PMC

---

Dietary “molecular” supplements

No supplement treats or cures ACD. Nutrition plans for these infants are designed by neonatology/dietetic teams. Breast milk is preferred when feeding becomes safe; many infants need TPN early. PMC+1

1. Human milk (mother’s milk or donor milk): supports immunity and gut health; may be given by tube when stable. AAP Publications+1

2. Human milk fortifier: adds protein/minerals to meet high NICU needs; used only when directed. AAP Publications

3. Vitamin D: supports bone/immune health; standard neonatal supplementation when enteral feeds begin. AAP Publications

4. Iron (timed): prevents anemia in growing infants on feeds; dosing individualized. AAP Publications

5. Electrolytes (Na/K/Cl): replace losses with diuretic therapy; strictly monitored. PubMed

6. Omega-3 fatty acids (via milk/fortified nutrition): general anti-inflammatory support; not ACD-specific therapy. AAP Publications

7. Zinc: for growth and wound healing in prolonged NICU stays. AAP Publications

8. Multivitamins: standard neonatal formulations to meet micronutrient needs. AAP Publications

9. Selenium: antioxidant trace element used in some NICU protocols. AAP Publications

10. Probiotics: sometimes used in preterm infants to reduce NEC risk; not disease-specific for ACD; use varies by center. AAP Publications

---

Immunity booster / regenerative / stem-cell” drugs

There are no approved regenerative or “stem-cell” medicines for ACD. Research in other neonatal lung diseases (like bronchopulmonary dysplasia, BPD) has tested mesenchymal stem cells (MSCs) and extracellular-vesicle/gene approaches in early-phase trials and animal models. These remain experimental, outside routine care for ACD. (No dosing is recommended here.) Nature+3stemcellsjournals.onlinelibrary.wiley.com+3PMC+3

• MSC therapy (intratracheal/IV): Phase I studies in preterm BPD suggest feasibility/safety signals; not disease-modifying proof for ACD. stemcellsjournals.onlinelibrary.wiley.com+1

• FOXF1-targeted experimental strategies (e.g., enhancer biology, stabilizers, nanoparticle delivery) show promise in lab/animal work but not in human ACD therapy. PMC+2Nature+2

• Endothelial progenitor/c-KIT+FOXF1+ cell approaches: effective in mouse lung-injury models; not tested in ACD infants. Frontiers

---

Procedures/surgeries

1. Bilateral lung transplantation
   What: surgical replacement of both lungs.
   Why: only intervention that can bypass the malformed capillary bed; considered mainly in atypical ACD survivors who are stable enough. Outcomes after infant transplant can be similar to other indications in selected cases. PMC

2. ECMO cannulation (veno-arterial or veno-venous)
   What: surgical/bedside procedure to place large cannulas for extracorporeal support.
   Why: bridge to diagnosis, recovery trial, or transplant listing when conventional therapy fails. Universitätsklinikum Regensburg

3. Open lung biopsy
   What: small surgical removal of lung tissue.
   Why: definitive histology when ACD is suspected and results will change decisions; ideally before ECMO. PMC

4. Cardiac catheterization with vasoreactivity testing; atrial septostomy in select cases
   What: invasive heart procedure; sometimes creates/opens an atrial communication.
   Why: assess hemodynamics, test iNO response; septostomy can off-load the right heart in refractory PH (center-specific). PubMed

5. Feeding access procedures (when long NICU course)
   What: central lines, and rarely gastrostomy in longer-term survivors.
   Why: secure nutrition/medication delivery when prolonged support is needed. PMC

---

Prevention points

1. Genetic counseling for families with a prior affected child or known FOXF1 variant. MedlinePlus

2. Prenatal testing (targeted FOXF1 testing; consider fetal MRI for lung volume in high-risk pregnancies). PMC

3. Deliver at a tertiary center with advanced NICU/ECMO/transplant links when ACD is suspected. ELSO

4. Early recognition of refractory pulmonary hypertension that does not respond to iNO and standard care. PMC

5. Avoid delays to diagnostic biopsy/genetic testing when results would guide care decisions. PMC

6. Infection prevention in NICU to avoid added lung stress. PMC

7. Careful ventilator strategies to limit barotrauma and oxygen toxicity. PMC

8. Echocardiography early to define physiology and exclude structural heart disease. PMC

9. Early consults (pulmonary hypertension specialists, genetics, palliative care). PubMed

10. Family education about the condition, expected course, and options (including comfort-focused care). PMC

---

When to see doctors (urgent signs)

• Immediately at birth if a full-term baby has fast breathing, blue color, or needs very high oxygen/support. PMC

• Any time in infancy if a previously well baby develops unexplained low oxygen, poor feeding, or signs of pulmonary hypertension. PMC

---

What to eat and what to avoid

• In the NICU, feeding is medical: many babies need IV nutrition first; feeds start only when safe. Human milk is preferred when feeds begin; it supports immunity and growth. AAP Publications+1

• Parents: do not give any over-the-counter supplements or herbs to a hospitalized infant. All nutrition and medicines must be prescribed by the team. (Supplements do not fix ACD.) PMC

• After discharge (rare, atypical cases), follow the team’s plan for milk, fortifiers, vitamins, and iron. Avoid high-salt foods or extra fluids unless advised. AAP Publications

---

FAQs

1. Is ACD the same as PPHN?
   No. ACD causes severe PPHN, but the root problem is missing/misaligned lung capillaries. Typical PPHN often responds to iNO; ACD often does not. PMC

2. Can medicines cure ACD?
   No. Medicines may help temporarily. They cannot build new capillaries. PMC

3. Can a baby outgrow ACD?
   Classic ACD does not improve with time. Atypical forms can present later and may have patchy disease, but they still need specialized care and sometimes transplant. PMC

4. How is ACD confirmed?
   By lung histology and FOXF1 genetic testing. PMC+1

5. Is ACD inherited?
   Most cases are new (de novo) changes, but familial cases occur. Genetic counseling helps explain recurrence risk. PMC

6. What is the role of iNO?
   iNO is standard for PPHN; in ACD it may help briefly or not at all. Brigham and Women’s Hospital+1

7. Do sildenafil or milrinone help?
   They can improve hemodynamics in PPHN and sometimes in atypical ACD, but responses vary and are often incomplete in classic ACD. PMC+2PMC+2

8. What about bosentan?
   Some neonatal data suggest possible benefit in PPHN; safety monitoring (liver) is essential; use remains center-specific. Cambridge University Press & Assessment

9. Is ECMO a cure?
   No. ECMO is a bridge (to diagnosis/decision or transplant). Universitätsklinikum Regensburg

10. Can lung transplant work?
    In selected infants (often atypical ACD), outcomes can be similar to other infant lung transplants. PMC

11. Are there experimental gene or stem-cell treatments?
    Yes, in labs and early trials for other lung diseases; none are approved for ACD. Nature+1

12. What other problems occur with ACD?
    Some babies have GI, heart, or kidney malformations. PMC

13. Can ACD be found before birth?
    Sometimes—by targeted genetic testing and fetal imaging in high-risk pregnancies. PMC

14. What should parents focus on?
    Partner closely with the NICU team, ask about goals of care, and seek genetic counseling and, when appropriate, transplant evaluation. PMC

15. Where can I read more?
    Peer-reviewed reviews on ACD and FOXF1 biology, pediatric pulmonary-hypertension guidelines, and ECMO guidance (AHA/ATS, ELSO). PMC+2PubMed+2

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 14, 2025.